HBM BioVentures

HBM BioVentures

Baar, Switzerland-based biotechnology investment company HBM BioVentures AG said Thursday it has held a final closing on its first fund at SFr765 million ($465 million). The company held a SFr517 million first closing in June and was able to up that amount by drawing in Swiss banks such as Bank Julius Baer & Co. as investors. Founded by Henri Maier, a former executive at Roche AG, the firm invests in privately and publicly quoted companies in the U.S. and Europe operating in the life sciences and medical technology industry segments. Ernst & Young is the firm’s auditor. — Joshua Jaffe www.TheDeal.com

COPYRIGHT 2001 The Deal LLC

COPYRIGHT 2001 Gale Group